Reporter brief
Glucosuria associated with SGLT2 inhibitor adherence and clinical outcomes in observational real-world study
What happened
This observational study examined whether urinary glucose (glucosuria) could serve as a marker of adherence to SGLT2 inhibitors and whether it correlated with clinical outcomes in routine clinical practice. No sample size or effect sizes were reported in the available information.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Cohort; Human.
Cohort 2 comprised 45,711 patients prescribed SGLT2 inhibitors with urinalysis performed within 6 months after initiation, from the Optum Labs Data Warehouse real-world data (2014-2023)
- Design
- Cohort
- Sample
- 45,711
- Journal
- Journal of the American Society of Nephrology (JASN)
- Published
- Sep 17, 2026
Effect size
All-cause mortality: HR 0.78 (95% CI 0.73-0.83); Heart failure hospitalization: HR 0.87 (95% CI 0.78-0.98); End-stage kidney disease: HR 0.73 (95% CI 0.58-0.91); Fractures: HR 1.00 (95% CI 0.95-1.06)
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the SGLT2 inhibitors timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.